Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scanner could help surgeons spot Left-Behind cancer Mid-Operation

NCT ID NCT06676943

Diagnosis Sponsor: University Hospitals Coventry and Warwickshire NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new type of PET-CT scanner that can scan a tumor right after it is removed from the body. Patients with prostate or head and neck cancer received a small amount of radioactive tracer before surgery, which sticks to cancer cells. After removal, the specimen was scanned to see if cancer cells reached the edge (margin). The scan results were compared to standard lab tests to see how accurate the new method is. If it works well, surgeons could use it during operations to make sure they remove all the cancer the first time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radioactive tracer (fluorodeoxyglucose or similar) injected before surgery
What this could lead to
If successful, this technique could help surgeons see during an operation whether they have removed all the cancer, reducing the need for extra treatments or second surgeries.
What could go wrong
This is a small pilot study with only 57 participants, so results may not apply to all cancer types. The scanner's accuracy needs to be confirmed against standard lab tests, and it may not work for all tumor locations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

57 people

The number who actually took part.

Started

Sep 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For prostate cancer patients: 1. At least 18 years old at time of consent. 2. Listed for Robotic Radical Prostatectomy. For head and neck cancer patients: 1. At least 18 years old at time of consent. 2. Listed for resection of oral squamous cell carcinoma head and neck cancer resection. 3. Specimen able to fit into Xeos Aura specimen container. Exclusion Criteria: For prostate cancer patients: 1. General or local contra-indications for resectional surgery. 2. Lacks capacity to provide informed consent. 3. Currently participating in another interventional research study that in the judgment of the investigator would negatively affect the participant and/or this study's data integrity. For head and neck cancer patients: 1. General or local contra-indications for resectional surgery. 2. Lacks capacity to provide informed consent. 3. Pregnant or breast feeding patient. 4. Currently participating in another interventional research study that in the judgment of the investigator would negatively affect the participant and/or this study's data integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms oral cavity squamous cell carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancers Prostate cancer surgery

Contacts and locations

Locations

  • University Hospitals Coventry and Warwickshire NHS Trust

    Coventry, CV2 2DX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.